225 related articles for article (PubMed ID: 28948002)
1. Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets.
Ding YH; Ma Y; Qian LY; Xu Q; Wang LH; Huang DS; Zou H
Oncotarget; 2017 Sep; 8(36):60673-60683. PubMed ID: 28948002
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions.
Haghbin H; Gangwani MK; Ravi SJK; Perisetti A; Aziz M; Goyal H; Nawras A; Sodeman T
Ann Gastroenterol; 2020; 33(6):603-614. PubMed ID: 33162737
[TBL] [Abstract][Full Text] [Related]
3. Circulating and local renin-angiotensin-aldosterone system express differently in atrial fibrillation patients with different types of mitral valvular disease.
Qian Y; Liu Y; Tang H; Zhou W; Jiang L; Li Y; Li N; Li M; Xiao X
J Renin Angiotensin Aldosterone Syst; 2013 Sep; 14(3):204-11. PubMed ID: 23077077
[TBL] [Abstract][Full Text] [Related]
4. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
Polyzos SA; Kountouras J; Zavos C; Tsiaousi E
Diabetes Obes Metab; 2010 May; 12(5):365-83. PubMed ID: 20415685
[TBL] [Abstract][Full Text] [Related]
5. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study).
Käräjämäki AJ; Pätsi OP; Savolainen M; Kesäniemi YA; Huikuri H; Ukkola O
PLoS One; 2015; 10(11):e0142937. PubMed ID: 26571029
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.
Targher G; Mantovani A; Pichiri I; Rigolon R; Dauriz M; Zoppini G; Morani G; Vassanelli C; Bonora E
Clin Sci (Lond); 2013 Sep; 125(6):301-9. PubMed ID: 23596966
[TBL] [Abstract][Full Text] [Related]
7. Doppler Tissue Evaluation of Atrial Conduction Properties in Patients With Non-alcoholic Fatty-liver Disease.
Ozveren O; Izgi C; Eroglu E; Simsek MA; Turer A; Kucukdurmaz Z; Cinar V; Degertekin M
Ultrason Imaging; 2016 May; 38(3):225-35. PubMed ID: 26157039
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease.
Goh GB; Pagadala MR; Dasarathy J; Unalp-Arida A; Sargent R; Hawkins C; Sourianarayanane A; Khiyami A; Yerian L; Pai R; McCullough AJ; Dasarathy S
Liver Int; 2015 Mar; 35(3):979-85. PubMed ID: 24905085
[TBL] [Abstract][Full Text] [Related]
9. Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease.
Biccirè FG; Bucci T; Menichelli D; Cammisotto V; Pignatelli P; Carnevale R; Pastori D
Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334916
[TBL] [Abstract][Full Text] [Related]
10. The role of angiotensin II in nonalcoholic steatohepatitis.
Matthew Morris E; Fletcher JA; Thyfault JP; Rector RS
Mol Cell Endocrinol; 2013 Sep; 378(1-2):29-40. PubMed ID: 22579612
[TBL] [Abstract][Full Text] [Related]
11. Identification of key genes increasing susceptibility to atrial fibrillation in nonalcoholic fatty liver disease and the potential mechanisms: mitochondrial dysfunction and systemic inflammation.
Zhong B; Xie Z; Zhang J; Xie X; Xie Y; Xie B; Wang J; Liu C
Front Pharmacol; 2024; 15():1360974. PubMed ID: 38549670
[No Abstract] [Full Text] [Related]
12. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea.
Linz D; Hohl M; Nickel A; Mahfoud F; Wagner M; Ewen S; Schotten U; Maack C; Wirth K; Böhm M
Hypertension; 2013 Oct; 62(4):767-74. PubMed ID: 23959548
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease.
Kaser S; Ebenbichler CF; Tilg H
Int J Clin Pract; 2010 Jun; 64(7):968-83. PubMed ID: 20584230
[TBL] [Abstract][Full Text] [Related]
14. Exploring immune related gene signatures and mechanisms linking non alcoholic fatty liver disease to atrial fibrillation through transcriptome data analysis.
Wu K; Zhu J; Ma Y; Zhou Y; Lin Q; Tu T; Liu Q
Sci Rep; 2023 Oct; 13(1):17548. PubMed ID: 37845390
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease.
Ferreira DM; Simão AL; Rodrigues CM; Castro RE
FEBS J; 2014 Jun; 281(11):2503-24. PubMed ID: 24702768
[TBL] [Abstract][Full Text] [Related]
16. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
17. [Effect of NF-κB on the pathogenic course of non-alcoholic fatty liver disease].
Wu L; Xie Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 42(4):463-467. PubMed ID: 28490707
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role.
Seccia TM; Caroccia B; Muiesan ML; Rossi GP
Int J Cardiol; 2016 Mar; 206():71-6. PubMed ID: 26774837
[TBL] [Abstract][Full Text] [Related]
19. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.
Lim S; Oh TJ; Koh KK
Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
